Launch of Alesion® LX Ophthalmic Solution 0.1% in Japan

November 27, 2019, Osaka, Japan – Santen Pharmaceutical Co., Ltd. (Chairman and CEO: Akira
Kurokawa; Head Office: Osaka; hereinafter, “Santen” ) and Mitsubishi Tanabe Pharma Corporation(President and Representative Director: Masayuki Mitsuka; Head Office: Osaka; hereinafter,“Mitsubishi Tanabe Pharma”) announced today that Santen has launched anti-allergenic
ophthalmic solution Alesion® LX Ophthalmic Solution 0.1% (JAN*: Epinastine Hydrochloride;
hereinafter, “Alesion LX Ophthalmic Solution”) in Japan, for which Santen and Mitsubishi Tanabe
Pharma had concluded a joint sales promotion contract .
Based on the joint sales promotion contract announced on September 20, 2019, Santen will
manufacture and distribute the newly launched

Alesion LX Ophthalmic Solution and Alesion®

Ophthalmic Solution 0.05% (JAN: Epinastine Hydrochloride; hereinafter, “Alesion OphthalmicSolution”), and Santen and Mitsubishi Tanabe Pharma will jointly conduct promotional activities tomedical institutions. In the promotional activities to medical institutions, Santen will be in charge ofophthalmic institutions, and Mitsubishi Tanabe Pharma will be in charge of non-ophthalmic medicalinstitutions.
Alesion LX Ophthalmic Solution is an ophthalmic solution based on an in-license from Nippon
Boehringer Ingelheim Co., Ltd. and was developed in Japan by Santen as a treatment for allergic
conjunctivitis. Alesion LX Ophthalmic Solution is a high-dose formulation of Alesion OphthalmicSolution, which has been marketed in Japan since 2013. Epinastine hydrochloride, the active
ingredient of Alesion LX Ophthalmic Solution, is histamine H1 receptor antagonist and suppresses
the release of chemical mediators from mast cells. The active ingredient of Alesion LX Ophthalmic
Solution can reach the eye tissues in higher amount and work there for a longer time, therefore,
the clinical trials conducted in Japan have demonstrated that eye itching and conjunctival redness
as the main symptoms of allergic conjunctivitis can be suppressed by applying twice a day. Inaddition, no serious side effects have been observed in either the eyes or the entire body.
As a specialized ophthalmic company, Santen expects that the joint promotional activities withMitsubishi Tanabe Pharma, which boasts access to a wide range of medical specialties, will help
Santen further contribute to a better quality of life (QOL) of patients. Mitsubishi Tanabe Pharma,
which sells the allergy treatment agent Rupafin® Tablets 10 mg, believes that the ophthalmic
solutions added to the oral medicine will help the company meet more extensive needs of patients.
Both companies will strive to conduct fair and appropriate promotional activities in order tocontribute to a better QOL of patients and more effective medical treatment for them by offering
this new choice of treatment.
Santen and Mitsubishi Tanabe Pharma have no plans to revise their full-year financial forecasts asa result of this product launch.
* Japanese Accepted Names for Pharmaceuticals

Product Characteristics
Alesion® LX Ophthalmic Solution is a high-concentration preservative-free formulation ofAlesion® Ophthalmic Solution.

Compared with Alesion® Ophthalmic Solution, Alesion® LX Ophthalmic Solution can keep theepinastine concentration in the conjunctivas higher for a longer time after instillation, with its
anti-allergenic effects remaining twice as long as those of the former.

Alesion® LX Ophthalmic Solution applied twice a day shows its efficacy for eye itching andconjunctival redness as the main symptoms of allergic conjunctivitis.
Product Name

Alesion® LX Ophthalmic Solution 0.1%

JAN

Epinastine hydrochloride

Dosage form

Colorless and clear aseptic aqueous eye drops

Indication

Allergic conjunctivitis

Dosage1 drop/time, twice a day (in the morning and evening)

Storage

Room temperature

Packaging

5 mL plastic container × 10

Retail Price

712.60 yen/mL

Insurance Notes

NoneApproval (Japan)

September 20, 2019

HVL Listing

November 27, 2019

Release (Japan)

November 27, 2019

Product Image

About Santen
As a specialized company dedicated to ophthalmology, Santen carries out research, development,
marketing, and sales of pharmaceuticals, over-the-counter products, and medical devices. Santenis the market leader for prescription ophthalmic pharmaceuticals in Japan and its products now
reach patients in over 60 countries. With scientific knowledge and organizational capabilities
nurtured over a nearly 130-year history, Santen provides products and services to contribute to thewell-being of patients, their loved ones and consequently to society. For more information, please
visit Santen’s website (www.santen.com).
About Mitsubishi Tanabe Pharma Corporation
Mitsubishi Tanabe Pharma, which was founded in 1678, has its headquarters in Doshomachi,
Osaka, which is the birthplace of Japan’s pharmaceutical industry. With business centered on
ethical pharmaceuticals, Mitsubishi Tanabe Pharma is a well-established company and has thelongest history of any listed pharmaceutical company in Japan. In accordance with the corporate
philosophy of “contributing to the healthier lives of people around the world through the creation ofpharmaceuticals,” the Company formulated the key concept of Open Up the Future under theMedium-Term Management Plan 16-20. Through the discovery of drugs that address unmet
medical needs, centered on its priority disease areas — immuno-inflammation, diabetes and kidney,
central nervous system, and vaccines — Mitsubishi Tanabe Pharma will strive to contribute to thehealth of patients around the world. For more information, go to https://www.mt-pharma.co.jp/e/Forward-looking Statements
Information provided in this press release contains forward-looking statements. The achievementof these forecasts is subject to risk and uncertainty from various sources. Therefore, please notethat the actual results may differ significantly from the forecasts. Business performance andfinancial conditions are subject to the effects of changes in regulations made by the governmentsof Japan and other nations concerning medical insurance, drug pricing and other systems, and tofluctuations in market variables such as interest rates and foreign exchange rates.

Contact
Santen Pharmaceutical Co., Ltd.

Mitsubishi Tanabe Pharma Corporation

Corporate Communications Group

Corporate Communications Department

Grand Front Osaka Tower A

Media contacts: TEL:+81 6 6205 5119

4-20, Ofukacho, Kita-ku, Osaka 530-8552, Japan

Investor contacts: TEL:+81 6 6205 5110

E-mail: ir@santen.com
Tel:+81-6-4802-9360